NCT01416038View on ClinicalTrials.gov

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
BIOLOGICAL

DPX-Survivac

Vaccine targeting survivin antigen will be administered subcutaneously.

DRUG

low dose cyclophosphamide (oral)

Low dose cyclophosphamide will be taken by mouth.

Trial Locations (7)

11501

Winthrop University Hospital, Mineola

14263

Roswell Park Cancer Institute, Buffalo

27710

Duke University Medical Center, Durham

75230

Mary Crowley Cancer Research Center, Dallas

97239

Oregon Health & Science University, Portland

B3H 1V7

Queen Elizabeth II Health Sciences Centre, Halifax

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

ImmunoVaccine Technologies, Inc. (IMV Inc.)

INDUSTRY

NCT01416038 - Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | Biotech Hunter | Biotech Hunter